search
Back to results

Measurement of Heart-carotid Pulse Wave Velocity (hcPWV) by Laser Doppler Vibrometry (LDV) (InSide-CC)

Primary Purpose

Hypertension, Aortic Aneurysm, Bicuspid Aortic Valve

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Laser doppler vibrometry (LDV), heart(cordium) carotid pulse wave velocity (ccPWV)
Blood pressure and heart rate measurement
carotid to femoral PWW measurement
Questionnaire completion
Sponsored by
Institut National de la Santé Et de la Recherche Médicale, France
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Hypertension focused on measuring stiffness, hypertension, ascending aorta

Eligibility Criteria

18 Years - 90 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Patients between 18 and 90 years of age in both sexes, who visit the hospital for MRI thoracic MRI as part of routine care. Enrolled in a social security plan or beneficiary of such a plan. Free, informed, written consent signed by the participant and the investigator (no later than the day of inclusion and prior to any examination required by the research). and before any examination required by the research and even before the thoracic MRI planned in the care setting). Exclusion Criteria: Individuals under court protection, guardianship or under curator. MRI examination done in an emergency context Patients with skin lesions (severe eczema, wounds, etc.) in the thorax or neck that do not allow the application of not allowing the application of the skin protection film on the area of interest; Allergies to the adhesive film. Patients who have a beard, which would make it difficult to apply an adhesive cast. Subjects who are not affiliated with social security or an equivalent plan. Refusal or linguistic or psychic incapacity to read the information and not object to the research. Patients with a serious pathology threatening the vital prognosis in the short and medium term (cancer metastatic cancer, end-stage renal failure, end-stage liver failure, end-stage heart failure) heart failure). Patients with a history of acute severe (II, IV) heart failure. Patients with progressive cardiovascular pathologies (unstable coronary artery disease, severe valvular disease,stroke, aortic dissection). Rhythm disorders: atrial fibrillation, high degree auriculoventricular block. Pregnant or breastfeeding women Person subject to an exclusion period for another research

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    Technique comparison

    Arm Description

    All patients will undergo successively LDV heart to carotid PWV and ascending aorta PWV by MRI, for comparison

    Outcomes

    Primary Outcome Measures

    Heart-carotid pulse wave velocity (hcPWV) measured by LDV compared to MRI
    Values of PWV obtained by LDV and by MRI will be compared.

    Secondary Outcome Measures

    Reproducibility of LDV heart-carotid pulse wave velocity (hcPWV)
    Measures will be duplicated and the average calculated, in case of discrepancy > 0.5 m/s, a third measurement is made and the median determined. Two series of measurements will be taken at 5minutes of interval.
    Validity of carotid to femoral pulse wave velocity (cfPWV) measured by LDV
    Values of cfPWV obtained by LDV will be also compared with values obtained by tonometry.
    Association of heart-carotid pulse wave velocity (hcPWV) measured by LDV with classical cardiovascular (CV) risk factors and disease
    The correlation coefficient and linear regression will be calculated.
    Acceptability of heart-carotid pulse wave velocity (hcPWV) measured by LDV compared with MRI
    A questionnaire of acceptability will be completed by the patient after the measurements.

    Full Information

    First Posted
    January 6, 2023
    Last Updated
    January 25, 2023
    Sponsor
    Institut National de la Santé Et de la Recherche Médicale, France
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05711693
    Brief Title
    Measurement of Heart-carotid Pulse Wave Velocity (hcPWV) by Laser Doppler Vibrometry (LDV)
    Acronym
    InSide-CC
    Official Title
    Integrated Silicon Photonics for Cardiovascular Disease Monitoring InSiDe-CC Clinical Validation of the Diagnostic Device (LDV) for the Measurement of Heart-carotid Pulse Wave Velocity (PWV) by Magnetic Resonance Imaging (MRI)
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    January 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    February 1, 2023 (Anticipated)
    Primary Completion Date
    February 1, 2024 (Anticipated)
    Study Completion Date
    July 1, 2024 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Institut National de la Santé Et de la Recherche Médicale, France

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Aortic stiffness is an important imaging biomarker of vascular aging. The ascending aorta is the most elastic segment, and it is excluded by reference non-invasive method carotid to femoral pulse wave velocity (PWV). We propose to use laser-doppler vibrometry (LDV) to record superficial vibrations generated by cardiac activity and arterial pulses for measuring heart carotid PWV, a surrogate for ascending aorta. The trial aims to demonstrate the equivalence between heart-carotid PWV made by laser-doppler vibrometry (LDV) with the reference MRI measurement (4D-FLOW MRI). As secondary objectives, A) we aim to assess the reproducibility of LDV, compared with MRI, B) show that aortic stiffness measured by LDV fulfils international recommendations, C) to study the association between PWV and age or other cardiovascular risk factors, D) assess the acceptability of the measurement. For this, we include 100 consecutive patients, 50 women, 50 men, scheduled for clinically indicated thoracic aorta MRI.
    Detailed Description
    Cardiovascular (CV) diseases and their risk factors are the leading causes of morbidity and mortality in the world. They are responsible for more than 17.3 million deaths per year worldwide, accounting for 30% of all causes of death. The measurement of arterial stiffness is useful to estimate the global CV risk with more precision than the simple point assessment of the classical cardiovascular risk factors. Carotid-femoral pulse wave velocity (cfPWV) by tonometry is the reference method. However, it excludes by principle the ascending aorta, which is the most distensible and physiologically the most important segment. The InSiDe project aims to measure heart - carotid pulse wave velocity (hcPWV) from the measurement of skin vibrations on the chest and neck by laser doppler vibrometry (LDV), enclosing principally the ascending aorta. This will allow the measurement and validation of a new biomarker that quantifies the stiffness of the ascending aorta. We have demonstrated a very good agreement of the LDV-based cfPWV with the reference technique by tonometry. Our hypothesis, based on physiological reasons, is that heart-carotid PWV will surpass carotid-femoral PWV as a biomarker of large artery stiffness. The trial aims to demonstrate the equivalence between heart-carotid PWV measured by laser-doppler vibrometry (LDV) with the reference MRI measurement (4D-FLOW MRI). MRI, the gold standard comparator is technically demanding and uncomfortable for the patient, much more expensive and not applicable at the general population level. It is therefore likely that measurement by laser-doppler vibrometry, without contact, more comfortable, acceptable and fast, could replace MRI for mass applications. For this, we include 100 consecutive patients, 50 women, 50 men, scheduled for clinically indicated thoracic aorta MRI. ENDPOINTS Primary endpoint: • Heart-carotid PWV measured by LDV. To evaluate the agreement between heart-carotid PWV measured by LDV and the same measurement made by MRI (plus 4D-FLOW MRI) of the thorax. Secondary endpoints: Reproducibility of the LDV hcPWV Measurement of LDV cfPWV compared with tonometry Association between PWV (hc, cf, LDV, MRI), and age, other risk factors Assessment of patient acceptability of the measurement Statistical analysis The statistical technique used will be the Bland - Altman plot and the corresponding bias assessment (mean Bland-Altman bias and limits of agreement, defined as the mean bias ±1.96 - standard deviation, are provided); the coefficient of variation (CV) will also be used. Description of the device being investigated: The LDV device, developed by the European consortium CARDIS (Medtronic,SIOS, iMEC, Tyndall Institute) uses two arrays with 6 laser beams. It is a non-invasive exploration, by category 1 laser without any risk for the patient and allows to measure the local arterial stiffness (to evaluate the heart-carotid PWV) and segmental without contact with the skin by using the LDV technique. In practice, this device allows the evaluation of the hcPWV from the measurement of skin vibrations on the chest and neck. Description of the device used as a comparator: The reference technique is MRI, used in combination with 4D-FLOW MRI, an innovative technique that allows full 3-dimensional anatomical coverage as well as velocity coding in all 3 directions, opening new and unique possibilities for visualizing and quantifying complex cardiovascular blood flow

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Hypertension, Aortic Aneurysm, Bicuspid Aortic Valve, Marfan Syndrome, Aortic Dilatation
    Keywords
    stiffness, hypertension, ascending aorta

    7. Study Design

    Primary Purpose
    Diagnostic
    Study Phase
    Not Applicable
    Interventional Study Model
    Single Group Assignment
    Model Description
    Comparison of methods
    Masking
    None (Open Label)
    Masking Description
    MRI doctors will be blinded concerning LDV PWV values. Doctors performing LDV will not have access to MRI reports. Data will be consolidated and database frozen before reconciling MRI and LDV data
    Allocation
    N/A
    Enrollment
    100 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Technique comparison
    Arm Type
    Experimental
    Arm Description
    All patients will undergo successively LDV heart to carotid PWV and ascending aorta PWV by MRI, for comparison
    Intervention Type
    Device
    Intervention Name(s)
    Laser doppler vibrometry (LDV), heart(cordium) carotid pulse wave velocity (ccPWV)
    Intervention Description
    Patients scheduled for thoracic aorta MRI will have LDV measurement of ccPWV. Both techniques will be compared
    Intervention Type
    Procedure
    Intervention Name(s)
    Blood pressure and heart rate measurement
    Intervention Description
    To all patients: - blood pressure and heart rate will be measured
    Intervention Type
    Device
    Intervention Name(s)
    carotid to femoral PWW measurement
    Intervention Description
    To all patients: - carotid to femoral PWW will be measured by LDV and tonometry for comparison
    Intervention Type
    Procedure
    Intervention Name(s)
    Questionnaire completion
    Intervention Description
    All patients will complete a questionnaire of acceptability
    Primary Outcome Measure Information:
    Title
    Heart-carotid pulse wave velocity (hcPWV) measured by LDV compared to MRI
    Description
    Values of PWV obtained by LDV and by MRI will be compared.
    Time Frame
    1 hour
    Secondary Outcome Measure Information:
    Title
    Reproducibility of LDV heart-carotid pulse wave velocity (hcPWV)
    Description
    Measures will be duplicated and the average calculated, in case of discrepancy > 0.5 m/s, a third measurement is made and the median determined. Two series of measurements will be taken at 5minutes of interval.
    Time Frame
    1 hour
    Title
    Validity of carotid to femoral pulse wave velocity (cfPWV) measured by LDV
    Description
    Values of cfPWV obtained by LDV will be also compared with values obtained by tonometry.
    Time Frame
    1 hour
    Title
    Association of heart-carotid pulse wave velocity (hcPWV) measured by LDV with classical cardiovascular (CV) risk factors and disease
    Description
    The correlation coefficient and linear regression will be calculated.
    Time Frame
    1 hour
    Title
    Acceptability of heart-carotid pulse wave velocity (hcPWV) measured by LDV compared with MRI
    Description
    A questionnaire of acceptability will be completed by the patient after the measurements.
    Time Frame
    1 hour

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    90 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Patients between 18 and 90 years of age in both sexes, who visit the hospital for MRI thoracic MRI as part of routine care. Enrolled in a social security plan or beneficiary of such a plan. Free, informed, written consent signed by the participant and the investigator (no later than the day of inclusion and prior to any examination required by the research). and before any examination required by the research and even before the thoracic MRI planned in the care setting). Exclusion Criteria: Individuals under court protection, guardianship or under curator. MRI examination done in an emergency context Patients with skin lesions (severe eczema, wounds, etc.) in the thorax or neck that do not allow the application of not allowing the application of the skin protection film on the area of interest; Allergies to the adhesive film. Patients who have a beard, which would make it difficult to apply an adhesive cast. Subjects who are not affiliated with social security or an equivalent plan. Refusal or linguistic or psychic incapacity to read the information and not object to the research. Patients with a serious pathology threatening the vital prognosis in the short and medium term (cancer metastatic cancer, end-stage renal failure, end-stage liver failure, end-stage heart failure) heart failure). Patients with a history of acute severe (II, IV) heart failure. Patients with progressive cardiovascular pathologies (unstable coronary artery disease, severe valvular disease,stroke, aortic dissection). Rhythm disorders: atrial fibrillation, high degree auriculoventricular block. Pregnant or breastfeeding women Person subject to an exclusion period for another research
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Pierre Boutouyrie
    Phone
    0156093991
    Email
    pierre.boutouyrie@aphp.fr
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Pierre Boutouyrie
    Organizational Affiliation
    Hôpital Européen Georges-Pompidou
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Learn more about this trial

    Measurement of Heart-carotid Pulse Wave Velocity (hcPWV) by Laser Doppler Vibrometry (LDV)

    We'll reach out to this number within 24 hrs